文献速递骨质疏松与代谢性骨病

二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂或钠-葡萄糖协同转运蛋白-2抑制剂真实世界使用中的骨折风险:观察性研究的系统综述与Meta分析

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
PubMed 文献 · Osteoporos Int · 2019-05-27

本Meta分析纳入观察性研究,评估二肽基肽酶-4抑制剂(DPP-4i)、胰高血糖素样肽-1受体激动剂(GLP-1ra)或钠-葡萄糖协同转运蛋白-2抑制剂(SGLT2i)使用与骨折风险的关联。结果显示DPP-4i(RR 0.83,95%CI 0.60-1.14;n=11)、GLP-1ra(RR 0.65,95%CI 0.24-1.74;n=4)或SGLT2i(RR 1.02,95%CI 0.91-1.16;n=4)与骨折风险均无显著关联,仅GLP-1ra与髋部骨折风险显著降低相关(RR 0.21,95%CI 0.04-0.98)。

要点

  • DPP-4i、GLP-1ra或SGLT2i使用与总体骨折风险无显著关联。
  • GLP-1ra使用与髋部骨折风险显著降低相关(RR 0.21,95%CI 0.04-0.98)。
  • 需进一步研究这些药物对骨折风险的长期影响,尤其在高危人群中。

核心结论

  • 累积真实世界证据不支持DPP-4i、GLP-1ra或SGLT2i使用与骨折风险之间存在关联。
  • 这些发现与随机对照试验的累积证据一起,应使政策制定者和医生放心,这些药物不太可能增加2型糖尿病患者的骨折风险。
  • 需进一步研究这些药物对骨折风险的长期影响,尤其在高危人群中。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Web of Science数据库以识别相关观察性研究。
  • 采用随机效应模型估计汇总相对危险度(RR)。

主要发现

  • DPP-4i使用与骨折风险无显著关联(RR 0.83,95%CI 0.60-1.14;n=11)。
  • GLP-1ra使用与骨折风险无显著关联(RR 0.65,95%CI 0.24-1.74;n=4)。
  • SGLT2i使用与骨折风险无显著关联(RR 1.02,95%CI 0.91-1.16;n=4)。
  • 在几乎所有亚组中,DPP-4i或GLP-1ra使用与骨折风险一致缺乏关联,但GLP-1ra使用与髋部骨折风险显著降低相关(RR 0.21,95%CI 0.04-0.98)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究这些药物对骨折风险的长期影响,尤其在高危人群中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In the present meta-analysis based on real-world data, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1ra), or sodium-glucose cotransporter-2 inhibitors (SGLT2i) was not associated with the risk of fracture. INTRODUCTION: Cumulative evidence from randomized control trials (RCTs) with limited fracture events showed that the use of DPP-4i, GLP-1ra, or SGLT2i may not affect the risk of fracture. However, additional insights from large population-based studies with routinely collected data on fracture events and an adequate amount of fracture events are necessary to draw firm conclusions. To refine and complement the results from RCTs, a systematic review and meta-analysis of observational studies were performed to investigate the association between the use of DPP-4i, GLP-1ra, or SGLT2i and the risk of fracture in real-world settings. METHODS: The PubMed and Web of Science databases were searched to identify relevant observational studies. A random-effect model was used to estimate the summary relative risks (RRs). RESULTS: The use of DPP-4i (RR 0.83, 95% CI [confidence interval] 0.60, 1.14; n = 11), GLP-1ra (RR 0.65, 95% CI 0.24, 1.74; n = 4), or SGLT2i (RR 1.02, 95% CI 0.91, 1.16; n = 4) was not associated with the risk of fracture. In general, there was a consistent lack of association between the use of DPP-4i or GLP-1ra and the risk of fracture across nearly all subgroups, except for a significantly reduced risk of hip fracture with the use of GLP-1ra (RR 0.21, 95% CI 0.04, 0.98). CONCLUSIONS: Cumulative real-world evidence does not support an association between the use of DPP-4i, GLP-1ra, or SGLT2i and the risk of fracture. Our findings, together with the cumulative evidence from RCTs, should reassure policy makers and medical practitioners that the use of these medications is unlikely to increase the risk of fracture among type 2 diabetes mellitus patients in general. Further studies need to investigate the long-term impact of these drugs on the fracture risk, particularly in high-risk populations.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hidayat K, Du X, Shi BM, et al. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int. 2019. PMID: 31134305. doi:10.1007/s00198-019-04968-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。